Community-Based Mass Ultrasonographic Screening of Hepatocellular Carcinoma among Thrombocytopenic Adults

Thrombocytopenia has been reported as a valid surrogate for liver cirrhosis and could be used to identify groups at high risk of hepatocellular carcinoma (HCC) for ultrasonographic (US) screening. We designed this two-stage community-based screening for HCC. In 2004, subjects (ages ≥40 years) were invited to undergo comprehensive health examinations, with 17,551 men (ages 63.0 ± 11.5 years) and 39,151 women (ages 59.9 ± 11.7 years) participating. Subjects with platelet counts <150 × 109/L or α-fetoprotein (AFP) >20 ng/mL were enrolled for the second-stage US screening; 3,242 subjects (5.7%; male/female, 1,415/1,827; age 66 ± 10 years) were candidates for US screening and 2,983 (92.2%) responded. Of 137 suspected cases, 124 (90.5%) complied with referral for confirmation and 72 (58.1%) were confirmed to be HCC cases (male/female, 41/31; age 68.1 ± 8.8 years). Screening with AFP, thrombocytopenia, or both could identify 0.64% (n = 364), 5.33% (n = 3,205), and 5.7% (n = 3,242) of the high-risk subjects from the population, estimated to include 50.5%, 54.5%, and 71.3% of all HCC cases. Among confirmed patients, tumor diameters were <3 cm for the 27 (37.5%) patients and 3 to 5 cm for the 23 (31.9%) patients. Only 5 (6.9%) patients' conditions were too advanced to be actively treated. This study enrolled only 5.7% of the participants for US, which cover 64.7% to 71.3% of the HCC cases. Most (93%) of the detected cases were caught early enough to undergo effective treatment modalities. This HCC screening protocol should be feasible, economical, and effective. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1813–21)

[1]  W. Lui,et al.  Mass screening of primary hepatocellular carcinoma by alpha-fetoprotein in a rural area of Taiwan--a dried blood spot method. , 2008, Liver.

[2]  M. Choi,et al.  Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series , 2007, European Radiology.

[3]  Sheng-Nan Lu,et al.  Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV‐endemic areas in an HBV‐endemic country: Geographic variations among 502 villages in southern Taiwan , 2007, Journal of gastroenterology and hepatology.

[4]  Sheng-Nan Lu,et al.  Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma , 2006, Cancer.

[5]  Sheng-Nan Lu,et al.  A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan , 2006, Antiviral therapy.

[6]  Chien-Jen Chen,et al.  Secular trends and geographic variations of hepatitis B virus and hepatitis C virus‐associated hepatocellular carcinoma in Taiwan , 2006, International journal of cancer.

[7]  H. Toyoda,et al.  Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  F. Izzo,et al.  Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). , 2006, Critical reviews in oncology/hematology.

[9]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[10]  K. Kaneko,et al.  Low preoperative platelet counts predict a high mortality after partial hepatectomy in patients with hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[11]  B. Koneru,et al.  Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma , 2005, Journal of Gastrointestinal Surgery.

[12]  M. Latteri,et al.  Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. , 2005, Journal of hepatology.

[13]  M. Omata,et al.  Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. , 2004, Gastroenterology.

[14]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[15]  B. Daniele,et al.  α-fetoprotein and ultrasonography screening for hepatocellular carcinoma , 2004 .

[16]  Y. Jeng,et al.  High α‐fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and β‐catenin mutations , 2004 .

[17]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[18]  H. Ishibashi,et al.  Optimal treatment strategy for elderly patients with hepatocellular carcinoma , 2004, Journal of gastroenterology and hepatology.

[19]  Y. Matsui,et al.  Positive Status of α-Fetoprotein and des-γ-Carboxy Prothrombin: Important Prognostic Factor for Recurrent Hepatocellular Carcinoma , 2004, World Journal of Surgery.

[20]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[21]  Alan D. Lopez,et al.  Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000 , 2002, BMC Cancer.

[22]  Alan D. Lopez,et al.  Global and regional estimates of cancer mortality and incidence by site: I. Application of regional cancer survival model to estimate cancer mortality distribution by site , 2002, BMC Cancer.

[23]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[24]  S. Duffy,et al.  Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan , 2002, International journal of cancer.

[25]  A. Andriulli,et al.  Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma , 2002, American Journal of Gastroenterology.

[26]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[27]  G. Rapaccini,et al.  Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy , 2001, Cancer.

[28]  M. Bernardi,et al.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. , 2001, Journal of hepatology.

[29]  B. McMahon,et al.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study , 2000, Hepatology.

[30]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[31]  A. Hettinger,et al.  Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. , 1998, Journal of Hepatology.

[32]  C. Chen,et al.  [Community-based hepatocellular carcinoma screening in seven townships in Taiwan]. , 1995, Journal of the Formosan Medical Association = Taiwan yi zhi.

[33]  H. Mizuo,et al.  Mass screening for hepatocellular carcinoma: Experience in Hokkaido, Japan , 1994, Journal of gastroenterology and hepatology.

[34]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[35]  Chien-Jen Chen,et al.  Epidemiologic Characteristics of Malignant Neoplasms in Taiwan: III. Stomach Cancer , 1988 .

[36]  C. Chu,et al.  Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. , 1986, Gastroenterology.

[37]  Tang Zy.  Treatment of primary liver cancer -- with special reference to the east part of China. , 1980 .

[38]  Michael M. Davis,et al.  National health insurance. , 1949, Scientific American.

[39]  C. Chu,et al.  Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. , 2007, Journal of hepatology.

[40]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[41]  K. Okita.  Clinical aspects of hepatocellular carcinoma in Japan. , 2006, Internal medicine.

[42]  K. McGlynn,et al.  Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. , 2006, Journal of hepatology.

[43]  Z. Tang.  Screening and early treatment of primary liver cancer--with special reference to the east part of China. , 1980, Annals of the Academy of Medicine, Singapore.